Dupilumab Reduces COPD Exacerbations
WASHINGTON -- Among chronic obstructive pulmonary disease (COPD) patients with type 2 inflammation at high risk…
Browsing Tag
Dupilumab
Dupixent® (dupilumab) Late-breaking Phase 3 COPD Results Presented at ATS and…
<!-- Name:DistributionId Value:8843470 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Dupixent® (dupilumab) Demonstrates Potential to Become First Biologic to Treat COPD…
<!-- Name:DistributionId Value:8793979 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Dupixent® (dupilumab) Approved by European Commission as First and Only Targeted…
<!-- Name:DistributionId Value:8791865 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Dupixent® (dupilumab) Late-Breaking Data at AAD Show Significant Improvements in…
<!-- Name:DistributionId Value:8790647 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Dupixent® (dupilumab) Application for Treatment of Chronic Spontaneous Urticaria…
<!-- Name:DistributionId Value:8782894 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Dupilumab Delivers in Erythrodermic Atopic Dermatitis
Patients with severe erythrodermic atopic dermatitis (AD) had significant improvements with…
Dupixent® (dupilumab) Approved by European Commission as the First and Only Targeted…
<!-- Name:DistributionId Value:8738545 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Dupixent® (dupilumab) Recommended for Expanded EU Approval by the CHMP to Treat…
<!-- Name:DistributionId Value:8737493 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Weekly Dupilumab Beneficial in Eosinophilic Esophagitis
Elana Gotkine
THURSDAY, Dec. 22, 2022 (HealthDay News) -- Subcutaneous dupilumab administered weekly is associated with improved histologic outcomes and…